PR Newswire

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalize…

New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, ...
Renal & Urology News

Sefaxersen Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial

Interim phase 3 IMAgINATION study data show monthly subcutaneous sefaxersen significantly reduces proteinuria (UPCR) at week 37 in adults with primary IgA nephropathy.
BioSpace

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment ...
PR Newswire

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) ...

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or ...